IPSEY and IPN Related Headlines
Go Back- National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare
- Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
- Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
- Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
- Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
- U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
- Ipsen presents long-term IQIRVO data at liver disease conference
- Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
- Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
- Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
- Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
- Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
IPSEY and IPN Related Press Releases
Go Back- National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare
- Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
- Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
- Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
- Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
- U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
- Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
- Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
- Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
- Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
- Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
